Naquotinib mesylate is a compound that blocks the activity of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), both of which are involved in driving the growth and proliferation of certain types of cancer cells. It targets EGFR, EGFR (L858R), EGFR (L858R)/T790M, EGFRExon 19 deletion, and EGFRExon 19 deletion/T790M.
EGFR-HER2 inhibitor Naquotinib mesylate is a research tool for studying and inhibiting EGFR-HER2 signaling pathways, which are critical in cancer progression, particularly in lung cancers.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
